| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
126,890,000 |
| Market
Cap: |
1.15(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.79 - $9.1 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers where there is an unmet medical need. Co. has one commercially approved product, VONJO™ (pacritinib), which has received approval in the U.S. by the U.S. Food and Drug Administration for the treatment of adult patients with intermediate or primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x 10^9/L.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
5,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$27,500 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
9,922,851 |
| Total Sell Value |
$0 |
$0 |
$0 |
$60,660,378 |
| Total People Sold |
0 |
0 |
0 |
5 |
| Total Sell Transactions |
0 |
0 |
0 |
29 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Orbimed Capital Gp Vi Llc |
10% Owner |
– – • |
2021-01-07 |
4 |
S |
$3.50 |
$7,000,000 |
I/I |
(2,000,000) |
7,520,600 |
|
36% |
|
| Seeley Bruce J. |
EVP, Chief Operating Officer |
• – – |
2020-07-01 |
4 |
A |
$0.98 |
$4,900 |
D/D |
5,000 |
37,500 |
|
- |
|
| Craig Adam R |
President and CEO |
• • – |
2020-07-01 |
4 |
A |
$0.98 |
$4,900 |
D/D |
5,000 |
5,000 |
|
- |
|
| Kirske David |
EVP, Chief Financial Officer |
• – – |
2020-07-01 |
4 |
A |
$0.98 |
$3,722 |
D/D |
3,798 |
3,798 |
|
- |
|
| Seeley Bruce J. |
EVP, Chief Operating Officer |
• – – |
2020-06-30 |
4 |
A |
$0.99 |
$493 |
D/D |
500 |
32,500 |
|
- |
|
| Orbimed Capital Gp Vi Llc |
10% Owner |
– – • |
2020-03-06 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
9,520,000 |
|
49% |
|
| Bvf Ii Gp Llc |
|
– – – |
2020-03-02 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,150,400 |
|
24% |
|
| Seeley Bruce J. |
EVP, Chief Operating Officer |
• – – |
2018-12-31 |
4 |
A |
$0.62 |
$312 |
D/D |
500 |
32,000 |
|
- |
|
| Seeley Bruce J. |
EVP, Chief Operating Officer |
• – – |
2018-06-30 |
4 |
A |
$2.30 |
$1,148 |
D/D |
500 |
31,500 |
|
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2018-02-09 |
4 |
B |
$3.00 |
$2,097,675 |
I/I |
699,225 |
1,295,582 |
1.5 |
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2018-02-09 |
4 |
B |
$3.00 |
$16,902,324 |
D/D |
5,634,108 |
483,708 |
2.45 |
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2018-02-09 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,487,294) |
596,357 |
|
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2018-02-09 |
4 |
D |
$0.00 |
$0 |
D/D |
(6,512,706) |
0 |
|
- |
|
| Metzger Michael A |
Director |
– • – |
2018-01-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,121 |
20,121 |
|
- |
|
| Love Richard L |
Director |
– • – |
2017-09-29 |
4 |
S |
$3.20 |
$3,123 |
D/D |
(976) |
73,718 |
|
- |
|
| Love Richard L |
Director |
– • – |
2017-09-28 |
4 |
S |
$3.19 |
$43,714 |
D/D |
(13,624) |
74,694 |
|
- |
|
| Isaly Samuel D |
10% Owner |
– – • |
2017-06-13 |
4 |
A |
$0.00 |
$0 |
I/I |
5,000,000 |
5,000,000 |
|
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2017-06-09 |
4 |
A |
$0.00 |
$0 |
I/I |
357,333 |
2,083,651 |
|
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2017-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
3,759,333 |
651,074 |
|
- |
|
| Telling Fred |
Director |
– • – |
2017-04-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
34,736 |
78,874 |
|
- |
|
| Love Richard L |
Director |
– • – |
2017-04-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
34,736 |
88,318 |
|
- |
|
| Nudelman Phillip M Phd |
Director |
– • – |
2017-04-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
39,698 |
73,129 |
|
- |
|
| Tuckson Reed Vaughn |
Director |
– • – |
2017-04-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
34,736 |
92,424 |
|
- |
|
| Perry Matthew D |
See Explanation of Responses |
– • – |
2017-04-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
34,736 |
43,139 |
|
- |
|
| Perry Matthew D |
See Explanation of Responses |
– • – |
2017-01-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,403 |
8,403 |
|
- |
|
229 Records found
|
|
Page 4 of 10 |
|
|
